Abstract:SCN–VAN connectivity may be an antidepressant target associated with depressive state changes and a predictor of treatment response to serotonin reuptake inhibitors. The within‐network hypoconnectivity in SCN and DMN may reflect a trait‐like abnormality in MDD. Lack of placebo control is a limitation of this study. In this study, the effects of antidepressants on large‐scale brain networks and the neural basis of individual differences in response were explored. A total of 41 patients with major depressive disorder (MDD) and 42 matched healthy controls (HCs) were scanned by resting‐state functional magnetic resonance imaging separately at baseline and after a 12‐week follow‐up. The patients with MDD received escitalopram for 12 weeks. After treatment, patients were classified into those with MDD in remission [MDDr, endpoint 17‐item Hamilton Depression Rating Scale (HAMD) total score ≤7] and those in nonremission (MDDnr). The human Brainnetome Atlas was used to define large‐scale networks and compute within‐ and between‐network resting‐state functional connectivity (rsFC). Results showed the decreased subcortical network (SCN)–ventral attention network (VAN) connectivity at baseline increased in patients with MDD after 12‐week treatment, and it was comparable with that of HCs. This change was only observed in patients with MDDr. However, the decreased within‐network rsFC in SCN and default mode network (DMN) persisted in all patients with MDD, including those with MDDr and MDDnr, after treatment. The strength of SCN–VAN connectivity at baseline was significantly negatively correlated with the reduction rate of HAMD score in all patients with MDD. Thus, SCN–VAN connectivity may be an antidepressant target associated with depressive state changes and a predictor of treatment response to serotonin reuptake inhibitors. The within‐network rsFC in SCN and DMN may reflect a trait‐like abnormality in MDD. These findings provide further insights into the mechanism of antidepressants and their individual differences in response. The trial name is "Appropriate technology study of MDD diagnosis and treatment based on objective indicators and measurement" (URL: http://www.chictr.org.cn/showproj.aspx?proj=21377; registration number: ChiCTR‐OOC‐17012566).

Identification of early candidate urine biomarkers for measure Escitalopram treatment response from major depressive disorder

Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response from Major Depressive Disorder

Predicting the efficacy of escitalopram in the treatment of depression through urinary proteome

A genome-wide association study of escitalopram treatment outcomes in patients with major depressive disorder

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Pilot Study of Genome-Wide DNA Methylation and Gene Expression for Treatment Response to Escitalopram in Panic Disorder.

Response Trajectories During Escitalopram Treatment of Patients with Major Depressive Disorder

Spatio-temporal dynamics of EEG features during sleep in major depressive disorder after treatment with escitalopram:A pilot study

Diurnal Alterations in Circadian Genes and Peptides in Major Depressive Disorder Before and after Escitalopram Treatment.

Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment.

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

A novel urinary metabolite signature for diagnosing major depressive disorder.

Spatio-temporal Dynamics of EEG Features During Sleep in Major Depressive Disorder after Treatment with Escitalopram: a Pilot Study

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis

Tissue-Specific Oxysterols As Predictors of Antidepressant (escitalopram) Treatment Response in Patients with Major Depressive Disorder

Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): protocol for a factorial randomised controlled trial

Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study

Identification and Validation of Urinary Metabolite Biomarkers for Major Depressive Disorder